Jupiter Endovascular, a medical technology company pioneering a new class of endovascular procedures with its proprietary Transforming Fixation (TFX) platform, announced the close of an oversubscribed Series B financing round that exceeded its $40 million target. The round was led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor.
The proceeds from the financing will be used to complete Jupiter’s pivotal SPIRARE II clinical trial, prepare for commercialization, and develop new clinical applications of its groundbreaking TFX platform.
The TFX technology, which powers Jupiter’s Vertex system, provides a new level of stability, control, and anatomical protection during catheter-based interventions. This advancement could redefine procedures across a range of complex cardiovascular conditions.
This financing milestone comes as Jupiter Endovascular achieves key regulatory and clinical progress. The company recently received FDA 510(k) clearance for the Vertex Catheter incorporating TFX. It will soon present first-in-human clinical data from its SPIRARE I trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 Conference in San Francisco on October 26. The SPIRARE I study, conducted in Europe, evaluated 10 patients with acute, intermediate-risk pulmonary embolism (PE) treated with the Vertex Pulmonary Embolectomy System.
The follow-up SPIRARE II pivotal trial, now enrolling patients, aims to include up to 145 participants across 25 sites in the U.S. and Europe. The trial’s endpoints will assess procedural safety, right heart function, and clinical improvement from the procedure through 30 days post-treatment.
Jupiter’s proprietary TFX platform is engineered to address one of the most significant limitations in endovascular medicine: maintaining catheter stability and control within the vasculature’s most challenging anatomies.
The Vertex system allows physicians to navigate flexibly in a relaxed state, then achieve rapid, stable fixation via saline pressurization during intervention before returning to its flexible form for repositioning or removal. This innovation enables safer and more effective access to previously difficult-to-reach sites, expanding the potential scope of minimally invasive therapies.
KEY QUOTES:
“Closing this oversubscribed Series B financing round reflects strong conviction in our mission to rewrite the rules of endovascular medicine using TFX technology. We’re energized by the support of this distinguished syndicate of investors as we tackle one of the greatest unmet needs in transcatheter interventions – the lack of stability and control physicians face while operating in complex cardiovascular anatomies – starting with pulmonary embolism.”
— Carl J. St. Bernard, Chief Executive Officer, Jupiter Endovascular
“Since the earliest days of endovascular medicine, the inability to maintain catheter control has been the single greatest barrier to the wider adoption of transcatheter therapies. Jupiter is addressing this vast unmet need with a revolutionary advance that can provide stability in even the most tortuous anatomies, unlocking new possibilities for the millions of patients who are being underserved with today’s intravascular approaches. We are proud to lead this round and to partner with Carl and the Jupiter team to bring this technological breakthrough to physicians and patients worldwide.”
— Deborah Kilpatrick, PhD, Partner, Sonder Capital
